DrugPatentWatch Database Preview
Drugs in Development Information for DDP-225
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug DDP-225?
DDP-225 is an investigational drug.
There have been 29 clinical trials for DDP-225.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.
The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Peking University, and Yuhong Li.
Summary for DDP-225
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 17 |
WIPO Patent Applications | 9 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 2 (2014-10-01) |
Vendors | 2 |
Recent Clinical Trials for DDP-225
Title | Sponsor | Phase |
---|---|---|
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC). | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC). | Henan Cancer Hospital | Phase 2 |
GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC | Guiyang Medical University | Phase 3 |
Clinical Trial Summary for DDP-225
Top disease conditions for DDP-225
Top clinical trial sponsors for DDP-225
US Patents for DDP-225
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |